David A. Betebenner

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 617 citations · Full text

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Hing L. Sham, Dale J. Kempf, Akhteruzammen Molla et al. · Antimicrobial Agents and Chemotherapy · 1998 · 468 citations · Full text

Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x _L from NMR and Parallel Synthesis

Andrew M. Petros, Jürgen Dinges, David J. Augeri et al. · Journal of Medicinal Chemistry · 2005 · 291 citations

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Dale J. Kempf, Hing L. Sham, Kennan C. Marsh et al. · Journal of Medicinal Chemistry · 1998 · 204 citations · Full text

Immunology, Pharmacotherapy, Antiviral Drug +18

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability:  Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-<scp>l</scp>-<i>cis</i>-4,5-methanoprolinenitrile-Based Inhibitors

David R. Magnin, Jeffrey A. Robl, Richard Sulsky et al. · Journal of Medicinal Chemistry · 2004 · 103 citations · Full text

Glycobiology, Methanoprolinenitrile-containing Dipeptide Mimetics, Pharmacotherapy +19